Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
uniQure N.V. (NASDAQ:QURE), a biotechnology company specializing in gene therapy, announced the outcomes of its 2025 Annual General Meeting of Shareholders held on June 11, 2025. Shareholders voted on several key proposals, including the reappointment of board members and executive compensation.
The shareholders approved the amendment to uniQure’s Amended and Restated 2014 Share Incentive Plan, which was proposed to increase the number of ordinary shares reserved for issuance. This amendment was initially approved by the board of directors on April 15, 2025, and became effective immediately following shareholder approval.
At the Annual Meeting, shareholders re-elected Matthew Kapusta as an executive director and Dr. Robert Gut and Dr. Jeremy Springhorn as non-executive directors, each to serve until the 2028 annual general meeting. Additionally, the compensation of the named executive officers was approved on an advisory basis.
Other resolutions passed at the meeting included the adoption of the 2024 Dutch statutory annual accounts and the treatment of results, authorization for the board to issue ordinary shares and grant rights to subscribe for ordinary shares, and reauthorization of the board to repurchase ordinary shares.
KPMG Accountants N.V. was appointed as the external auditors for the financial year 2025. The voting results for all proposals are detailed in the definitive proxy statement filed with the SEC on April 28, 2025.
The information disclosed in this article is based on the company’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.